《生命科学》 2022, 34(6): 653-662

表观调控分子HMGN5在肿瘤中的研究进展

牟珈慧^1,2 , 任　进^1,2,*

¹中国科学院上海药物研究所，上海 201203 ²中国科学院大学，北京 100049

摘　要：

高迁移率族核小体结合蛋白5 (high-mobility group nucleosome-binding protein 5, HMGN5) 属于高迁移率族N (HMGN) 家族，是一种广泛存在于真核生物染色质内的非组蛋白，可通过与核小体结合调节染色质结构的“开放”与“关闭”，从而影响下游基因的表达。多项临床研究发现HMGN5 在不同类型肿瘤组织中都存在表达上调，可调控包括人前列腺癌、膀胱癌、肺癌、乳腺癌、胶质瘤在内的多种肿瘤细胞的增殖、迁移及耐药等生物学过程。本文总结了 HMGN5 在不同肿瘤中的表达情况与意义，以及它在肿瘤发生发展中涉及的分子调控，并探讨了其在肿瘤治疗中的潜在价值。

通讯作者：任　进 , Email:jren@cdser.simm.ac.cn

Research advances of epigenetic regulator HMGN5 in tumors

MOU Jia-Hui^1,2 , REN Jin^1,2,*

¹Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China ²University of Chinese Academy of Sciences, Beijing 100049, China

Abstract:

High-mobility group nucleosome-binding protein 5 (HMGN5) belongs to the high-mobility group N (HMGN) family that is a group of non-histone proteins and widely exists in eukaryotic chromatin. HMGN5 regulates the chromatin structure by binding to nucleosome, thereby affecting the expression of downstream genes. It has been reported HMGN5 is highly expressed in many kinds of cancers including prostate cancer, bladder cancer, lung cancer, breast cancer, glioma, etc. Additionally, HMGN5 regulates tumor cell proliferation, migration, drug resistance and other tumor-related biological process. We summarize the current knowledge concerning the differential expression of HMGN5 in cancers, as well as the molecular mechnism of HMGN5 in tumorigenesis and cancer development. Based on this, we highlight the potential value of HMGN5 in the treatment of cancers.

Communication Author：REN Jin , Email:jren@cdser.simm.ac.cn